Reconstruction in Women with T4 Breast Cancer after Neoadjuvant Chemotherapy: When Is It Safe?
Adult
Breast
/ pathology
Breast Neoplasms
/ diagnosis
Chemotherapy, Adjuvant
Female
Follow-Up Studies
Humans
Incidence
Mammaplasty
/ adverse effects
Mastectomy
/ adverse effects
Middle Aged
Neoadjuvant Therapy
Neoplasm Recurrence, Local
/ epidemiology
Neoplasm Staging
Postoperative Complications
/ epidemiology
Prospective Studies
Radiotherapy, Adjuvant
/ statistics & numerical data
Reoperation
/ statistics & numerical data
Retrospective Studies
Time Factors
Time-to-Treatment
/ statistics & numerical data
Journal
Journal of the American College of Surgeons
ISSN: 1879-1190
Titre abrégé: J Am Coll Surg
Pays: United States
ID NLM: 9431305
Informations de publication
Date de publication:
08 2021
08 2021
Historique:
received:
11
03
2021
revised:
09
04
2021
accepted:
12
04
2021
pubmed:
7
5
2021
medline:
26
10
2021
entrez:
6
5
2021
Statut:
ppublish
Résumé
Despite limited evidence regarding its safety, immediate reconstruction (IR) is increasingly offered to women with T4 breast cancer. We compared outcomes after IR, delayed reconstruction (DR), and no reconstruction (NR) in patients treated with neoadjuvant chemotherapy (NAC) and postmastectomy radiation therapy (PMRT) for T4 disease. We retrospectively identified consecutive women with T4 tumors treated with trimodality therapy from January 2007 through December 2019. Clinicopathologic characteristics, complications requiring reoperation, time to PMRT, and recurrence patterns were compared. The cumulative incidence of local recurrence (LR) was estimated using Kaplan-Meier methods. Of the 269 women identified, the median (IQR) age was 52 (45-62) years; 164 women (61%) had T4d disease. Forty-five women (17%) had IR, 41 (15%) had DR, and 183 (68%) had NR. IR was independently associated with T4a-c disease (odds ratio [OR], 5.75; 95% CI, 2.57-12.87; p < 0.001) and younger age (OR 0.91; 95% CI, 0.86-0.94; p < 0.001). The risk of complications after IR was 22% overall and 46% in T4d patients (6/13), compared with 4.4% overall for NR and 7.3% for DR (p < 0.001). IR was associated with >8-week interval to PMRT (p < 0.001). At a median (range) follow-up of 4.2 (0.2-13) years, the median time to first recurrence was 18 months and was similar between groups (p = 0.13). The cumulative incidence of LR was 16% for T4d disease and 2.2% for T4a-c disease (p < 0.001). After IR, women with T4 tumors, particularly T4d disease, experienced delayed initiation of adjuvant treatment and substantial morbidity, suggesting that an interval of >18 months between mastectomy and reconstruction is advisable.
Sections du résumé
BACKGROUND
Despite limited evidence regarding its safety, immediate reconstruction (IR) is increasingly offered to women with T4 breast cancer. We compared outcomes after IR, delayed reconstruction (DR), and no reconstruction (NR) in patients treated with neoadjuvant chemotherapy (NAC) and postmastectomy radiation therapy (PMRT) for T4 disease.
STUDY DESIGN
We retrospectively identified consecutive women with T4 tumors treated with trimodality therapy from January 2007 through December 2019. Clinicopathologic characteristics, complications requiring reoperation, time to PMRT, and recurrence patterns were compared. The cumulative incidence of local recurrence (LR) was estimated using Kaplan-Meier methods.
RESULTS
Of the 269 women identified, the median (IQR) age was 52 (45-62) years; 164 women (61%) had T4d disease. Forty-five women (17%) had IR, 41 (15%) had DR, and 183 (68%) had NR. IR was independently associated with T4a-c disease (odds ratio [OR], 5.75; 95% CI, 2.57-12.87; p < 0.001) and younger age (OR 0.91; 95% CI, 0.86-0.94; p < 0.001). The risk of complications after IR was 22% overall and 46% in T4d patients (6/13), compared with 4.4% overall for NR and 7.3% for DR (p < 0.001). IR was associated with >8-week interval to PMRT (p < 0.001). At a median (range) follow-up of 4.2 (0.2-13) years, the median time to first recurrence was 18 months and was similar between groups (p = 0.13). The cumulative incidence of LR was 16% for T4d disease and 2.2% for T4a-c disease (p < 0.001).
CONCLUSIONS
After IR, women with T4 tumors, particularly T4d disease, experienced delayed initiation of adjuvant treatment and substantial morbidity, suggesting that an interval of >18 months between mastectomy and reconstruction is advisable.
Identifiants
pubmed: 33957258
pii: S1072-7515(21)00330-6
doi: 10.1016/j.jamcollsurg.2021.04.016
pmc: PMC9466002
mid: NIHMS1832426
pii:
doi:
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Langues
eng
Sous-ensembles de citation
IM
Pagination
285-293Subventions
Organisme : NCI NIH HHS
ID : P30 CA008748
Pays : United States
Informations de copyright
Copyright © 2021 American College of Surgeons. Published by Elsevier Inc. All rights reserved.
Références
J Surg Oncol. 2019 Jan;119(1):79-87
pubmed: 30480805
Cancer. 2017 Sep 15;123(18):3460-3467
pubmed: 28513834
JAMA Surg. 2020 Dec 1;155(12):1142-1150
pubmed: 33052412
J Surg Oncol. 2009 Sep 1;100(3):248-51
pubmed: 19330813
Am Soc Clin Oncol Educ Book. 2017;37:93-105
pubmed: 28561684
Breast. 2021 Feb;55:55-62
pubmed: 33341706
Ann Surg Oncol. 2021 Apr;28(4):2155-2168
pubmed: 32974696
Aesthet Surg J. 2020 Nov 17;40(Suppl 2):S1-S12
pubmed: 33202011
Int J Radiat Oncol Biol Phys. 2008 Jan 1;70(1):43-50
pubmed: 17855006
J Clin Oncol. 2012 Nov 10;30(32):3960-6
pubmed: 23032615
Breast J. 2020 Mar;26(3):384-390
pubmed: 31448540
JAMA Surg. 2014 Oct;149(10):1068-76
pubmed: 25133469
Int J Radiat Oncol Biol Phys. 2012 Mar 15;82(4):e587-93
pubmed: 22197232
Plast Reconstr Surg. 2015 Jun;135(6):1509-1517
pubmed: 25742523
J Clin Oncol. 2003 Feb 1;21(3):555-63
pubmed: 12560449
Ann Surg Oncol. 2016 Dec;23(Suppl 5):642-648
pubmed: 27638670
Breast Cancer Res Treat. 2019 Jul;176(2):337-347
pubmed: 31020469
Breast J. 2018 Jul;24(4):567-573
pubmed: 29316048
Cancer. 2018 Nov 15;124(22):4314-4321
pubmed: 30307616
Breast. 2017 Oct;35:48-54
pubmed: 28649032
Int J Radiat Oncol Biol Phys. 2021 Mar 15;109(4):1007-1018
pubmed: 33371964
Clin Breast Cancer. 2017 Jun;17(3):204-210
pubmed: 28065399
Breast Cancer Res Treat. 2017 Oct;165(3):779-781
pubmed: 28674763